<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961931</url>
  </required_header>
  <id_info>
    <org_study_id>EMPA - 1 - AMZ</org_study_id>
    <nct_id>NCT04961931</nct_id>
  </id_info>
  <brief_title>Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease</brief_title>
  <official_title>Effect of Empagliflozin on Urinary Excretion of Adenosine and on Markers of Osteocyte Function and Glomerular Damage in Diabetic and Non-diabetic Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lodz</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of orally drugs for&#xD;
      the treatment of type 2 diabetes. These drugs decrease plasma glucose levels by inhibiting&#xD;
      its reabsorption in the proximal tubules of the kidney. They have an attractive clinical&#xD;
      efficacy profile, including glycemic control, weight loss, and lowering blood pressure. SGLT2&#xD;
      inhibitors have also been reported to reduce the risk of severe adverse cardiovascular events&#xD;
      and progression of diabetic kidney disease. SGLT2 is expressed in the kidney, while its&#xD;
      expression in other tissues is most likely negligible or absent.&#xD;
&#xD;
      SGLT2 dilates the supply vessels to the glomerulus thereby promoting hyperfiltration. In&#xD;
      animal models SGLT2 has been shown to reduce the excretion of macular dense adenosine, which&#xD;
      may contribute to the excessive glomerular filtration rate as a result of vasodilation of the&#xD;
      afferent vessels. Adenosine, unlike other vascular regions, increases the tension in the&#xD;
      walls of the vessels supplying blood to the glomerulus. The role of adenosine in humans in&#xD;
      this regard is poorly defined, although treatment with empagliflozin has recently been shown&#xD;
      to increase the urinary excretion of adenosine in type 1 diabetic patients with controlled&#xD;
      hyperglycemia. Our working hypothesis is that the SGLT2 inhibitor empagliflozin may reduce&#xD;
      the hyperfiltration of residual nephrons by increasing adenosine production, which affects&#xD;
      the contraction of the afferent arterioles, and this effect occurs in various types of&#xD;
      nephropathy.&#xD;
&#xD;
      In addition, it has been described that SGLT2 inhibitors may affect individual parameters of&#xD;
      calcium-phosphate metabolism, leading to changes in bone mineral density and an increase in&#xD;
      bone resorption marker SGLT2 inhibitors also stimulate renal, proximal phosphate&#xD;
      reabsorption. Increased phosphate reabsorption triggers the secretion of fibroblast growth&#xD;
      factor 23 (FGF23). FGF23 inhibits the production of 1,25-dihydroxyvitamin D (the biologically&#xD;
      active form of vitamin D), which reduces the absorption of calcium from the gastrointestinal&#xD;
      tract, thereby stimulating the secretion of parathyroid hormone (PTH). In the conducted&#xD;
      studies, it was found that SGLT2 inhibitors increase the concentration of serum phosphorus,&#xD;
      FGF23 in the plasma and PTH in the plasma, while lowering the level of 1,25-dihydroxyvitamin&#xD;
      D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be prospective, interventional and will be conducted in two parallel groups&#xD;
      selected on the basis of clinical diagnosis. It is planned to enroll 60 patients aged 18-70&#xD;
      years under outpatient nephrological care, with impaired excretory function of the kidneys&#xD;
      (eGFR 20-60 ml / min / 1.73 m3), with proteinuria above 0.5-3 g / l in the morning urine&#xD;
      sample , including 30 nondiabetic and 30 diabetic patients t.2 and 20 healthy control&#xD;
      subjects (no microalbuminuria and no impaired renal function with eGFR&gt; 90 ml / min /&#xD;
      1.73m3). After the patients are familiarized with the objectives of the study and the&#xD;
      informed consent signed, the following procedures will be performed.&#xD;
&#xD;
      After signing the consent, basic biochemical tests will be performed in both groups to assess&#xD;
      the concentration of protein, albumin, calcium, phosphate, adenosine and creatinine in the&#xD;
      morning urine sample, creatinine, calcium, phosphate, PTH, bacterial alkaline phosphatase&#xD;
      (BAP), 1.25 vitamin D, sclerostins, FGF23, serum Klotho proteins, eGFR, plasma glucose. The&#xD;
      tests will be repeated after 7 days of taking empagliflozin in a dose of 10 mg a day. On days&#xD;
      1 and 7, patients will be given an intravenous glucose 5% solution at a dose of 240 mg&#xD;
      glucose / kg body weight in the first 15 minutes to induce a controlled hyperglycaemia state&#xD;
      in the first 15 minutes, this will increase their blood glucose by 125 mg / dL in 15 minutes&#xD;
      followed by 10-12 mg glucose / kg body weight, under glycemic control to maintain a&#xD;
      concentration of 200 mg / dL ± 5% for 120 minutes. Stability of serum glucose levels during&#xD;
      this period will be maintained by adjusting the rate of intravenous glucose infusion based on&#xD;
      blood glucose measurements, every 15 minutes. After 2 hours of infusion, additional blood&#xD;
      will be drawn for the determination of glucose and renal parameters and after 100 ml of urine&#xD;
      for determination. adenosine, albumin and creatinine concentrations. In healthy subjects from&#xD;
      the control group, the above basic blood and urine biochemical tests will be performed once.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will be prospective, interventional and will be conducted in two parallel groups selected on the basis of clinical diagnosis (diabetic nephropathy or other chronic nephropathies).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>albuminuria</measure>
    <time_frame>7 days</time_frame>
    <description>ratio of albumin to creatinine in urine in mg/g</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum calcium concentration</measure>
    <time_frame>7 days</time_frame>
    <description>serum calcium level in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urine calcium concentration</measure>
    <time_frame>7 days</time_frame>
    <description>level of calcium in urine in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urine adenosine</measure>
    <time_frame>7 days</time_frame>
    <description>adenosine in urine in µmol/mmol creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urine phosphorus concetration</measure>
    <time_frame>7 days</time_frame>
    <description>serum phosphorus level in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum Fibroblast growth factor 23 concentration</measure>
    <time_frame>7 days</time_frame>
    <description>serum Fibroblast growth factor 23 level in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum parathormone concentration</measure>
    <time_frame>7 days</time_frame>
    <description>serum parathormone level in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum Klotho concentration</measure>
    <time_frame>7 days</time_frame>
    <description>serum Klotho level in ng/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum Bone alkaline phosphatase concentration</measure>
    <time_frame>7 days</time_frame>
    <description>serum Bone alkaline phosphatase level in µg/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum 1,25(OH)2D concentration</measure>
    <time_frame>7 days</time_frame>
    <description>serum 1,25(OH)2D level in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum sclerostin concentration</measure>
    <time_frame>7 days</time_frame>
    <description>serum sclerostin level in pmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urine phosphorus concetration</measure>
    <time_frame>7 days</time_frame>
    <description>phosphorus in urine in mmol/l</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Chronic Kidney Disease stage3</condition>
  <arm_group>
    <arm_group_label>diabetes group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After qualifying for the study subjects with diabetes and chornic kidney disease received oral empagliflozin 10 mg once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-diabetes group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After qualifying for the study subjects with chronic kidney disease without diabetes received oral empagliflozin 10 mg once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After qualifying for the study healthy subjects received oral empagliflozin 10 mg once daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>diabetes group</arm_group_label>
    <arm_group_label>non-diabetes group</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  type 2 diabetes complicated by diabetic nephropathy (first group), non-diabetic&#xD;
             nephropathy (second group) or healthy subjects&#xD;
&#xD;
          -  Angiotensin-converting enzyme inhibitor or antagonists of angiotensin receptor&#xD;
             blockers in the stable dose for the 4 months&#xD;
&#xD;
          -  age 18 - 70 years&#xD;
&#xD;
          -  stable clinical condition for the last 3 months&#xD;
&#xD;
          -  GFR 25-60 ml / min / 1.73 m2&#xD;
&#xD;
          -  proteinuria 0.5-3 g / day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetes mellitus other than t.2&#xD;
&#xD;
          -  have taken SGLT2 inhibitors in the last 4 weeks or have ever had an intolerance to&#xD;
             SGLT2 inhibitors in the past&#xD;
&#xD;
          -  acute kidney damage&#xD;
&#xD;
          -  systolic blood pressure &lt;90 mmHg&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  acute inflammation&#xD;
&#xD;
          -  liver failure&#xD;
&#xD;
          -  heart failure&gt; 2. NYHA grade&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  patients with impaired consciousness and testers with insufficient management in the&#xD;
             past.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ireneusz Staroń</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Lodz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michał Nowicki, Prof</last_name>
    <phone>+48 42 201 4400</phone>
    <email>nefro@wp.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Masajtis-Zagajewska, PhD</last_name>
    <phone>+48 606 558 005</phone>
    <email>anna.masajtis-zagajewska@umed.lodz.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nephrology, Hypertension and Kidney Transplantation</name>
      <address>
        <city>Łódź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <phone>00482014400</phone>
      <email>nefro@wp.pl</email>
    </contact>
    <contact_backup>
      <last_name>Anna Masajtis-Zagajewska, MD</last_name>
      <phone>+48608558005</phone>
      <email>anna.masajtis-zagajewska@umed.lodz.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Michał Nowicki, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lodz</investigator_affiliation>
    <investigator_full_name>Michal Nowicki</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>SGLT2 inhibitors</keyword>
  <keyword>adenosine</keyword>
  <keyword>calcium-phosphate metabolism</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>diabetes</keyword>
  <keyword>non-diabetes</keyword>
  <keyword>albuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

